Key Highlights

  • ALMS shares are trading up 11.40% to $10.55, rebounding after Monday's roughly 57% crash.
  • The prior session's plunge was triggered by disappointing Phase 2b LUMUS trial results for envdeucitinib in systemic lupus erythematosus, which missed primary and secondary endpoints in the overall population.
  • Oppenheimer called the initial selloff an overreaction and reiterated an Outperform rating, cutting its price target to $37.
  • Morgan Stanley, Wells Fargo, and HC Wainwright also maintained bullish stances, citing robust responses in the IFNG-high biomarker subgroup, which may represent 60% to 80% of lupus patients.
  • Investors remain focused on Alumis staying on track to file an NDA for envdeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.

Shares Bounce Back After Monday's Steep Selloff

Alumis (NASDAQ:ALMS) shares are rebounding sharply, clawing back a portion of Monday's roughly 57% crash that followed disappointing Phase 2b LUMUS trial results for lead candidate envdeucitinib in systemic lupus erythematosus. Alumis is a South San Francisco-based clinical-stage biopharmaceutical company developing precision medicines for autoimmune and immune-mediated diseases, with envdeucitinib, an allosteric TYK2 inhibitor, also being evaluated for plaque psoriasis.

The trial missed both its primary and secondary endpoints in the overall study population, triggering the sharp initial decline, but a closer look at a specific patient subgroup has since drawn a wave of analyst support.

Analysts Defend the Stock, Pointing to a Key Biomarker Subgroup

Oppenheimer called the initial selloff an overreaction and reiterated an Outperform rating, though it cut its price target to $37 from a higher prior level. Morgan Stanley, Wells Fargo, and HC Wainwright, which upgraded the stock to Buy, all maintained bullish stances, citing what they described as robust responses in the IFNG-high biomarker subgroup, a population that may represent 60% to 80% of systemic lupus erythematosus patients.

Psoriasis Filing Timeline Remains a Separate Catalyst

Investors are also focused on Alumis remaining on track to file a New Drug Application for envdeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026, a catalyst that analysts see as still intact despite the lupus setback. Alumis's broader pipeline also includes A-005, a CNS-penetrant TYK2 inhibitor targeting neuroinflammatory conditions, and lonigutamab, an IGF-1R monoclonal antibody in development for thyroid eye disease.

Can the Biomarker Data Rebuild the Bull Case?

Alumis shares are recovering as analysts shift focus toward the subgroup data and the unaffected psoriasis program, though the stock remains well below its pre-selloff levels. Further detail on the biomarker-selected lupus strategy and progress toward the fourth-quarter psoriasis filing will likely determine whether today's bounce holds.